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Purpose/Objective: Permanent breast seed implantation 
(PBSI) is a brachytherapy technique where Pd-103 seeds are 
implanted directly into the clinical target volume (CTV). 
Seeds used in PBSI emit short range photons that confine 
exposure to the target tissue resulting in a high degree of 
dose conformality. However there are limitations such as; 
suboptimal dose distribution due to the inherent low photon 
energy (21 keV), or misplacement/migration of seeds, and 
inactive seeds left after treatment. To address these 
limitations we have investigated the application of gold 
nanoparticles (AuNPs), which studies have shown can be 
functionalized by binding radioisotopes and various 
monoclonal antibodies to its surface. Numerous studies have 
also suggested that AuNPs exhibit radiation enhancing 
properties. The goal of this research then is to design an 
unsealed seed comprising of Pd-103 radiolabeled AuNPs to 
enhance radiotherapy while improving dose uniformity 
through physical diffusion of radioactive nanoparticles. In this 
initial phase of the study, we outline the design of the AuNP 
seed and characterize AuNP release from the seed. 
Materials and Methods: Ultrapure medical grade sodium 
alginate (Pronova™ NovaMatrix, Norway) was initially tested 
to identify the concentration most suitable for forming seeds. 
Concentrated non-radioactive 30nm AuNPs (BBI Solutions, UK) 
were mixed with sodium alginate, and polymerized using 10% 
calcium chloride to form AuNP embedded seeds. To develop 
a model for nanoparticle release phantoms were implanted 
with seeds, followed by mice bearing MDA-MB-231 human 
adenocarcinoma breast xenografts. Seeds made with 6% 
(w/v) alginate and 0.12mg AuNP were implanted into the 
tumours using a modified template device. A microCT 
(Scanco Medical μCT100, Switzerland) was used to image the 
tumours ex vivo at 1, 7, 14, and 28 days post implantation. 
AuNP concentrations were determined using a radiodensity 
calibration curve. 
Results: Preliminary results indicate that alginate is an 
appropriate material for implantation and that its stability 
can be controlled by optimizing its weight to volume 
concentration. Seeds made from very low viscosity-
guluronate (VLV-G) alginate (6%, 8%, 10% wt/vol) were able 
to release AuNP into phantoms (Figure 1a). MicroCT imaging 
revealed that 6% alginate seeds released AuNP 1.4 and 1.5 
times faster than 8% and 10% seeds respectively. Preliminary 
animal data using 6% alginate seeds and 30nm AuNP also show 
local AuNP release (Figure 2a). Tumour bearing mice 
implanted with seeds retained only 67% of the initial AuNP 
amount by 28days.  
 
Conclusions: The overarching vision is to develop a novel 
form of brachytherapy using a nanoparticle based radioactive 
source that may offer a solution for improving local dose 
distribution for interstitially implanted sources. Preliminary 
data has shown that by embedding AuNPs into calcium 
alginate seeds, controlled release and diffusion can be 
achieved.  
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Purpose/Objective: APBI is currently considered a viable 
treatment option in early-stage breast cancer patients. 
Mostly due to the rising need to treat patients outside clinical 
trials, in 2009 two consensus statements (CS) were created 
by ASTRO (American Society for Radiation Oncology) and 
GEC-ESTRO (Groupe Européen de Curiethérapie-European 
Society for Radiotherapy and Oncology). More recently, 
guidelines from ABS (American Brachytherapy Society) were 
also published. This helps the train of thought Radiation 
Oncologists have to undergo concerning the decision for the 
most appropriate adjuvant radiation treatment modality in 
early-stage breast cancer patients. Nevertheless, during that 
process, doubts may emerge due to the lack of parallelism 
among the three guidelines that can lead to different risk 
group stratification/treatment indications for the same 
patient. Our study aimed at comparing the rate of suitable 
and unsuitable patients for APBI according to the three 
guidelines. As a secondary objective survival and relapse 
rates were also addressed. 
Materials and Methods: 81 patients submitted to APBI, in a 
single-institution, were retrospectively analyzed (treated 
from 2003 to 2013) and then categorized according to 
indication for treatment as 'suitable', 'cautionary' and 
'unsuitable' (ASTRO), as 'low risk', 'intermediate risk' and 'high 
risk' (GEC-ESTRO), and as 'acceptable' and 'not acceptable' 
